Research assessment of patients with psychotic depression: The STOP-PD approach

Psychiatric Annals

Volumn 36, Issue 1, 2006, Pages 48-56

  Flint, Alastair J ^a   Schaffer, Ayal ^a   Meyers, Barnett S ^a   Rothschild, Anthony J ^a   Mulsant, Benoit H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 31644446939     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20060101-03     Document Type: Review

References (41)

1. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53(8):680-690.
2. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department; 2001.
3. Anton RF, Burch EA. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990;147(9):1203-1208.
4. Parker G, Hadzi-Pavlovic D, Hickie I, et al. Psychotic depression: a review and clinical experience. Aust N Z J Psychiatry. 1991;25(2):169-80.
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
6. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
7. Kalali A, Gibertini M, Kobak K, et al. A reliability study of the new GRID-HAMD - initial results. Presented at: 41st American College of Neuropsychopharmacology Annual Meeting; December 8-12, 2002; San Juan, Puerto Rico.
8. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia. 3rd ed. New York, NY: New York State Psychiatric Institute, Biometrics Research; 1979.
9. Kendler KS, Glazer WM, Margenstern H. Dimensions of delusional experience. Am J Psychiatry. 1983;140(4):466-469.
10. Roose SP, Glassman AH, Walsh BT, Woodring S, Vital-Herne J. Depression, delusions and suicide. Am J Psychiatry. 1983;140(9):1159-1162.
11. Beck AT, Kovacs M, Weissman M. Scale for suicide ideation. J Consult Clin Psychol. 1979;47:343.
12. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. 'Vascular Depression' hypothesis. Arch Gen Psychiatry. 1997; 54(10):915-922.
13. Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry. 1999;56(8):713-718.
14. Simpson S, Baldwin RC, Jackson A, Burns AS. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med. 1998;28(5):1015-1026.
15. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 2000; 57(3):285-290.
16. O'Brien J, Ames D, Chiu E, Schweitzer I, Desmond P, Tress B. Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ. 1998;317(7164):982-984.
17. Golden CJ. The Stroop Color and Word Test. Chicago, IL: Stoetling; 1978.
18. Mattis S. Dementia Rating Scale Professional Manual. Odessa Fl: Psychological Assessment Resources; 1989.
19. Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry. 1991;148(1):102-105.
20. Eaton WW, Armenian HK, Gallo JJ, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care. 1996;19(10):1097-1102.
21. Harris E, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998 Jul;173:11-53.
22. Januzzi JL, Stern TA, Pasternak RC, DeSanctis RW. The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med. 2000;160(13):1913-1921.
23. Jonas BS, Franks P, Ingram DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Fam Med. 1997;6(1):43-49.
24. Williams LS, Ghose SS, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry. 2004;161(6):1090-1095.
25. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998; 351(9112):1303-1307.
26. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999;47(1):30-39.
27. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
28. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ. 1996; 155(5):519-527.
29. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992; 41(3):237-248.
30. Meyers BS, Sirey J, Bruce ML. Who goes where? Clinical and sociodemographic predictors of service site in mental health outpatients. Presented at: National Institutes of Mental Health Conference on Improving the Condition of People with Mental Illness; 1997; Washington, DC.
31. Sackeim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10(2):96-104.
32. Oquendo MA, Baca-Garcia E, Kartachov A, et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry. 2003;64(7): 825-833.
33. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 Suppl):1-45.
34. Mulsant BH, Haskett RF, Prudic J, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry. 1997;154(4):559-561.
35. Applebaum PS, Grisso T. MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR). Sarasota, FL: Professional Resource Press; 2001.
36. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF 36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
37. Lingjaerde O, Ahlfors UG, Bech P, Dencker SI, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
38. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
39. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 May; 154:672-676.
40. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W. ed. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976:534-537.
41. Psychopharmacology Research Branch, National Institute of Mental Health. Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976:217-222.